Search Result

Results for "

partial

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (127) Adenosine Receptor (9) Adenylate Cyclase (4) Adrenergic Receptor (35) Amino Acid Derivatives (6) Androgen Receptor (4) Angiotensin Receptor (4) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (6) AP-1 (2) Apolipoprotein (1) Apoptosis (5) Arrestin (5) ATP Citrate Lyase (1) Autophagy (3) Bacterial (9) Beta-secretase (2) Biochemical Assay Reagents (8) Calcium Channel (16) Cannabinoid Receptor (9) Carboxylesterase (CES) (1) Chloride Channel (1) Cholecystokinin Receptor (1) Cholinesterase (ChE) (2) COX (1) CRFR (2) CXCR (1) Cytochrome P450 (6) Dopamine Receptor (77) Drug Isomer (1) Drug Metabolite (12) Dynamin (1) EGFR (1) Endogenous Metabolite (18) Endothelin Receptor (1) Epigenetic Reader Domain (1) Epoxide Hydrolase (1) ERK (2) Estrogen Receptor/ERR (8) Factor Xa (3) Free Fatty Acid Receptor (4) Fungal (2) FXR (1) G Protein-coupled Receptor Kinase (GRK) (1) GABA Receptor (44) GCGR (3) Glucocorticoid Receptor (3) Glucokinase (1) Glycosidase (2) GlyT (1) GPR109A (1) Histamine Receptor (6) Histone Methyltransferase (1) HSP (1) Hydroxycarboxylic Acid Receptor (HCAR) (1) iGluR (18) Influenza Virus (1) Insecticide (1) Interleukin Related (1) IRE1 (1) Isocitrate Dehydrogenase (IDH) (1) Isotope-Labeled Compounds (38) JAK (2) Leukotriene Receptor (2) Ligands for E3 Ligase (1) Lipoxygenase (1) LPL Receptor (2) LXR (3) mAChR (18) Melanocortin Receptor (3) Melatonin Receptor (2) mGluR (6) Microtubule/Tubulin (1) nAChR (48) Neurokinin Receptor (1) Neuropeptide FF Receptor (3) NF-κB (4) NO Synthase (4) Nuclear Factor of activated T Cells (NFAT) (2) Opioid Receptor (33) Oxytocin Receptor (1) P2Y Receptor (1) p38 MAPK (5) Parasite (3) PDHK (1) PERK (1) PGE synthase (1) Phosphatase (1) PKG (2) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (2) PPAR (26) Prostaglandin Receptor (5) PROTACs (1) Protease Activated Receptor (PAR) (1) RAR/RXR (2) Reactive Oxygen Species (4) Reference Standards (24) Renin (3) SARS-CoV (1) Serotonin Transporter (16) Sigma Receptor (3) Sodium Channel (13) Somatostatin Receptor (4) Taste Receptor (1) Thrombin (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Trace Amine-associated Receptor (TAAR) (1) Trk Receptor (2) TRP Channel (3) TSH Receptor (1) Vasopressin Receptor (2) VD/VDR (1) Virus Protease (4) β-catenin (4) γ-secretase (1)
By Research Areas:	Cancer (80) Cardiovascular Disease (64) Endocrinology (28) Infection (23) Inflammation/Immunology (63) Metabolic Disease (68) Neurological Disease (314)
Click Chemistry:	Azide (1) Alkynes (3)
Oligonucleotides:	Disintegrants (1) Emulsifiers (1) Polymers (1)

512

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-103418

Dopamine D2 receptor agonist-3	Dopamine Receptor	Neurological Disease
Dopamine D2 receptor agonist-3 (compound 3) is a selective D2 receptor partial agonist and Dopamine D3 receptor antagonist (with pEC₅₀ of 8.3 and <5.5 respectively) .

HY-123813

CCX-777	Arrestin	Cancer
CCX-777 is a partial agonist of β-arrestin-2 recruitment to ACKR3 (atypical chemokine receptor 3) .

HY-10019

Varenicline CP 526555	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10020

Varenicline Hydrochloride CP 526555 hydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019A

Varenicline dihydrochloride CP 526555 dihydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-106206

AL-6598	Prostaglandin Receptor	Cardiovascular Disease
AL-6598 is a partial agonist of the DP and EP prostaglandin receptors. AL-6598 reduces intraocular pressure and is used in glaucoma research .

HY-107680

3-Pyr-Cytisine 3-Pyr-Cyt	nAChR	Neurological Disease
3-Pyr-Cytisine (3-Pyr-Cyt) is a cytisine derivative. 3-Pyr-Cytisine is a very weak α4β2 nAChR partial agonist that has been studied as an antidepressant .

HY-19082

Y-23684	GABA Receptor	Neurological Disease
Y-23684 is a partial agonist of benzodiazepine receptor (BZR) with anticonvulsant and anxiolytic activities. Y-23684 can be used in the research of treatment of anxiety disorders .

HY-110142

Thermopsidine CC4	nAChR	Neurological Disease
Thermopsidine (CC4) is a selective partial agonist at α4β2/α6β2 nAChR with EC₅₀ values of 2.2 μM target α4β2 .

HY-145698

UCSF678	5-HT Receptor	Neurological Disease
UCSF678 is a 42 nM arrestin-biased partial agonist at the 5-HT_5AR with a more restricted off-target profile and decreased assay liabilities. UCSF678 is a selective probe with which to study the function of the 5-HT_5AR .

HY-10021

Varenicline Tartrate CP 526555-18	nAChR ERK p38 MAPK	Others Neurological Disease Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-171182

D3017	Endogenous Metabolite	Neurological Disease
D3017 is the main metabolite of D2624, which has oral bioactivity and anti-convulsant effects. D3017 ED₅₀ value is 1.5 mg/kg in mice, and it can be used for research on severe generalized tonic-clonic seizures (grand mal) and complex partial epilepsy .

HY-121249

Capeserod hydrochloride SL65.0155	5-HT Receptor	Neurological Disease
Capeserod hydrochloride (SL65.0155) is a 5-HT_4(e) receptor partial agonist (K_i=0.6 nM) with potent cognitive enhancing properties. Capeserod hydrochloride acts as a partial agonist in cells expressing 5-HT_4(b) and 5-HT_4(e) splice variants, stimulating cAMP production with IC₅₀ values of 244 and 29 nM, respectively. Capeserod hydrochloride is used in the study of memory impairment and dementia .

HY-103548

GSK9027	Glucocorticoid Receptor	Endocrinology
GSK9027, as a non-steroidal glucocorticoid receptor (GR) agonist, behaves as a partial agonist on the 2×glucocorticoid response element (GRE) reporter system, and achieves intrinsic activities relative to dexamethasone .

HY-10021R

Varenicline Tartrate (Standard) CP 526555-18 (Standard)	Reference Standards nAChR ERK p38 MAPK	Others Neurological Disease
Varenicline (Tartrate) (Standard) is the analytical standard of Varenicline (Tartrate). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019R

Varenicline (Standard) CP 526555 (Standard)	Reference Standards nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (Standard) is the analytical standard of Varenicline. This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019AR

Varenicline dihydrochloride (Standard) CP 526555 dihydrochloride (Standard)	Reference Standards nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (dihydrochloride) (Standard) is the analytical standard of Varenicline (dihydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10020R

Varenicline Hydrochloride (Standard) CP 526555 hydrochloride (Standard)	Reference Standards nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (Hydrochloride) (Standard) is the analytical standard of Varenicline (Hydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S1

Varenicline-15N,13C,d2 CP 526555-15N,13C,d2	nAChR Isotope-Labeled Compounds	Neurological Disease Inflammation/Immunology Cancer
Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-155707

MOR agonist-3	Dopamine Receptor	Inflammation/Immunology
MOR agonist-3 (Compound 84) is a D3R/MOR antagonist/partial agonist a(K_i 382 nM and 55.2 nM respectively). MOR agonist-3 has the potential to produce analgesic effects through MOR (μ-opioid receptor) (HY-149337) partial agonists and to reduce opioid abuse through D3R antagonists. MOR agonist-3 can be used in the treatment of inflammation and neuropathic pain research .

HY-W062702

BMS-933043	nAChR	Neurological Disease
BMS-933043 is a potent and selective α7 nACh receptor partial agonist. BMS-933043 attenuates the cognitive impairment in mice and can be utilized in research related to cognitive dysfunction in schizophrenia .

HY-106964A

(Rac)-S 16924	5-HT Receptor	Neurological Disease
(Rac)-S 16924 is a partial agonist of the 5-HT1A receptor. (Rac)-S 16924 regulates signaling through its interaction with the 5-HT1A receptor, and (Rac)-S 16924 can stabilize the receptor in its G-protein-coupled conformation without fully activating it, which may affect intracellular signaling pathways associated with this receptor. (Rac)-S 16924 can be used to study the 5-HT1A receptor in mental disorders, especially schizophrenia .

HY-109065

Minesapride	5-HT Receptor	Others
Minesapride is a partial agonist with a highly selective serotonin 4 (5-HT4) receptor. Minesapride enhances gastrointestinal peristalsis and colon transport by activating the 5-HT4 receptor. Minesapride increases bowel movements and suppresses visceral allergic reactions. Minesapride can be used in the study of constipation-type irritable bowel syndrome (IBS-C) .

HY-59201A

A-582941 dihydrochloride	nAChR 5-HT Receptor	Neurological Disease
A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with K_is of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT₃ receptor with a K_i of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research .

HY-13479

EC144	HSP	Cancer
EC144 is a potent and selective inhibitor of heat shock protein 90 (Hsp90) with an IC₅₀ of 1.1 nM. EC144 inhibits tumor growth and causes partial tumor regressions. EC144 has the potential for the research of cancer diseases . EC144 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10019AS1

Varenicline-d4 hydrochloride	Isotope-Labeled Compounds nAChR	Inflammation/Immunology
Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-103476

Ro15-4513	GABA Receptor	Neurological Disease
Ro15-4513, imidazobenzodiazepinone derivative, is a partial inverse agonist of benzodiazepine receptor (BZR) . Ro15-4513 is a potent ethanol antagonist . Ro15-4513 has anti-anxiety effect . Ro15-4513 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-103476R

Ro15-4513 (Standard)	GABA Receptor	Neurological Disease
Ro15-4513 (Standard) is the analytical standard of Ro15-4513. This product is intended for research and analytical applications. Ro15-4513, imidazobenzodiazepinone derivative, is a partial inverse agonist of benzodiazepine receptor (BZR) . Ro15-4513 is a potent ethanol antagonist . Ro15-4513 has anti-anxiety effect . Ro15-4513 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-14417

VU0155041	mGluR	Neurological Disease
VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC₅₀s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD) .

HY-14417B

VU0155041 sodium	mGluR	Neurological Disease
VU0155041 sodium is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC₅₀s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD) .

HY-118097

GW0072	PPAR	Others
GW0072 is a partial agonist of PPARγ and does not directly bind to the AF-2 helix of PPARγ, resulting in specific partial receptor transcriptional activation properties .

HY-Y1176

Isonipecotic acid	GABA Receptor	Neurological Disease
Isonipecotic acid is a GABAA receptor partial agonist .

HY-U00066

Cicloprolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Cicloprolol is a partial β 1-adrenoceptor agonist .

HY-107480

YK11 1 Publications Verification	Androgen Receptor	Metabolic Disease
YK11 is a partial agonist of androgen receptor, with osteogenic activity.

HY-114703

Eslicarbazepine 1 Publications Verification BIA 2-194	Beta-secretase Sodium Channel	Neurological Disease
Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-U00216

NNC45-0781	Estrogen Receptor/ERR	Metabolic Disease
NNC45-0781 is a tissue-selective estrogen partial-agonist.

HY-118299

JYL 1511	TRP Channel	Inflammation/Immunology
JYL 1511 is a partial agonist of vanilloid receptor VR1 .

HY-B0570

Decamethonium Bromide 1 Publications Verification	nAChR	Neurological Disease
Decamethonium Bromide is a nicotinic AChR partial agonist and neuromuscular blocking agent.

HY-N15087

Lunatoic acid A	Bacterial	Infection
Lunatoic acid A has anti-mould (partial) and bacterial (individual) effects .

HY-14958A

Pardoprunox hydrochloride SLV-308 hydrochloride; DU-126891 hydrochloride	5-HT Receptor Adrenergic Receptor Dopamine Receptor	Neurological Disease Endocrinology
Pardoprunox (SLV-308) hydrochloride is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC₅₀s of 8, 9.2, and 6.3, respectively .

HY-116257

GSK-7227	PPAR PDHK	Others
GSK-7227 (compound 32) is a PPARδ partial agonist with the activity of regulating the expression of related genes. GSK-7227 has partial agonist effects on PPARδ target genes CPT1a and PDK4 in skeletal muscle cells.

HY-14958

Pardoprunox SLV-308; DU-126891	5-HT Receptor Adrenergic Receptor Dopamine Receptor	Neurological Disease Endocrinology
Pardoprunox (SLV-308) is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC₅₀s of 8, 9.2, and 6.3, respectively .

HY-N15088

Lunatoic acid B	Bacterial	Infection
Lunatoic acid B has anti-mould (partial) and bacterial (individual) effects .

HY-17622

Tavilermide 2 Publications Verification MIM-D3	Trk Receptor	Inflammation/Immunology
Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	nAChR	Metabolic Disease Cancer
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-117526

(-)-Mesembrine	Endogenous Metabolite	Neurological Disease
(-)-Mesembrine, a psychoactive alkaloid, is a partial racemate in S. strictum and S. tortuosum in smaller amounts .

HY-101639A

CP-409092 hydrochloride	GABA Receptor	Neurological Disease
CP-409092 hydrochloride is a partial agonist of GABA_A receptor, with anti-anxiety activity .

HY-116888

BFE-55	Adrenergic Receptor	Endocrinology
BFE-55 is a derivative of befunolol and a β-adrenergic partial agonist .

HY-100140

Pipequaline 1 Publications Verification PK-8165	GABA Receptor	Neurological Disease
Pipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity .

HY-121393

Imidazenil	GABA Receptor	Neurological Disease
Imidazenil is a partial positive allosteric modulator of GABA_A receptors with anxiolytic, antipanic and anticonvulsant activities.

Cat. No.	Product Name	Type

HY-Y0850O

Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) PVA (Mw 31000-50000, 87-89% hydrolyzed); Poly(Ethenol) (Mw 31000-50000, 87-89% hydrolyzed)	Drug Delivery
Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) is a synthetic polymer derived from polyvinyl acetate through partial or complete hydroxylation .

HY-W259767

3-Iodo-L-phenylalanine	Cell Assay Reagents
3-Iodo-L-phenylalanine is an unnatural amino acid that can be used for partial codon redistribution. 3-Iodo-L-phenylalanine has a high efficiency in Ser AGU codon reassignment, and also has a certain effect in Ser UCG codon reassignment. 3-Iodo-L-phenylalanine can be used in the study of genetic code expansion and protein engineering .

HY-Y1365

Gelatins

Thickeners

Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy ^[1][2][3].

HY-154924

Thio-NADP S-NADP	Biochemical Assay Reagents
Thio-NADP (S-NADP) is a nicotinic acid adenine dinucleotide phosphate (NAADP) inhibitor. Thio-NADP activates partial Ca ²⁺ release .

HY-121855

1-Monoelaidin

Glycerol 1-monoelaidate; α-Monoelaidin

Drug Delivery

Monoeladin is an ester derivative of glycerin and oleic acid, which are commonly found in various vegetable and animal fats. Monoeladin has unique chemical properties that make it an important intermediate in the biosynthesis of other lipid molecules, especially in the formation of triglycerides and phospholipids. It also plays a role in food science as a partial replacement for saturated fat, which has been linked to an increased risk of heart disease.

Cat. No.	Product Name	Target	Research Area

HY-P3617

Glucagon (22-29)	GCGR	Metabolic Disease
Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca ²⁺ pump in liver plasma membranes independently of adenylate cyclase activation .

HY-P2625

GLP-2(3-33) 2 Publications Verification	GCGR	Metabolic Disease
GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM) .

HY-P5535

Invopressin OCE-205	Vasopressin Receptor	Inflammation/Immunology
Invopressin (Compound 42) is a vasopressin V1A receptor partial agonist (EC₅₀: 1.0 nM). Invopressin can be used for research of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites .

HY-P5358

YFLLRNP	Protease Activated Receptor (PAR)	Others
YFLLRNP is a biological active peptide. (a partial agonist of PAR-1. YFLLRNP selectively active G12/13 signaling pathway without activating Gq or Gi pathways at low concentrations. YFLLRNP (60 μM))

HY-P5517

SNNF(N-Me)GA(N-Me)ILSS	Peptides	Others
SNNF(N-Me)GA(N-Me)ILSS is a biological active peptide. (Double N-methylated derivatives of amyloidogenic and cytotoxic partial IAPP sequence)

HY-P5516

SNNF(N-Me)GA(N-Me)IL	Peptides	Others
SNNF(N-Me)GA(N-Me)IL is a biological active peptide. (Double N-methylated derivatives of amyloidogenic and cytotoxic partial IAPP sequence)

HY-106234

ZP 120C	Opioid Receptor	Cardiovascular Disease Neurological Disease
ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia .

HY-P3563

[Lys4] Sarafotoxin S6c	Endothelin Receptor	Cardiovascular Disease
[Lys4] Sarafotoxin S6c, a sarafotoxin analogue, is a potent and partial agonist of endothelin receptor. [Lys4] Sarafotoxin S6c elicits contraction of pig coronary artery, with an EC₅₀ of 1.5 nM .

HY-P10325

Kalata B7	Vasopressin Receptor Oxytocin Receptor	Cardiovascular Disease
Kalata B7 is a cyclotide that can be isolated from Oldenlandia affinis DC (Rubiaceae) and possesses membrane-permeating capabilities. Kalata B7 is also a partial agonist of oxytocin and vasopressin V_1a receptors .

HY-P7060

NT 13 TPPT	iGluR	Neurological Disease
NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide. NT 13 is a partial N-methyl-D-aspartate receptor (NMDAR) agonist used in the study of depression, anxiety, and other related diseases.

HY-P1294

α-Helical CRF(9-41)	CRFR	Neurological Disease
α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with K_B of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC₅₀ of 140 nM .

HY-P1294A

α-Helical CRF(9-41) TFA	CRFR	Neurological Disease
α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with K_B of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC₅₀ of 140 nM .

HY-P10377

GUB03385	Neuropeptide FF Receptor	Metabolic Disease
GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC₅₀: 0.4 nM) and NPFF2R (partial agonist, EC₅₀: 20 nM). GUB03385 has anti-obesity effect .

HY-P1316

Ac-RYYRWK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d of 0.071 nM, but has no affinity for µ-, κ- or δ-opioid receptors .

HY-P5515

F(N-Me)GA(N-Me)IL	Peptides	Others
F(N-Me)GA(N-Me)IL is a biological active peptide. (Double N-methylated derivatives of amyloidogenic and cytotoxic partial IAPP sequence were found to be devoid of β-sheet structure, amyloidogenicity and cytotoxicity, The derivatives were able to interact with the native sequences and inhibit amyloid formation)

HY-P1316A

Ac-RYYRWK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRWK-NH2 is a potent and selective partial agonist for the nociceptin receptor (NOP), [ ³H]Ac-RYYRWK-NH2 binds to rat cortical membranes ORL1 with a K_d of 0.071 nM, but has no affinity for μ-, κ- or δ-opioid receptors .

HY-P0227

SHU 9119 3 Publications Verification	Melanocortin Receptor	Metabolic Disease
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC₅₀ values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.

HY-P3343A

hFSH-β-(33-53) (TFA) 1 Publications Verification	Estrogen Receptor/ERR	Cancer
hFSH-β-(33-53) TFA, a thiol-containing peptide which corresponds to a second FSH receptor-binding domain, is a FSHR (follicle-stimulating hormone receptor) antagonist. hFSH-β-(33-53) TFA inhibits binding of FSH to receptor and is a partial agonist of estradiol synthesis in Sertoli cells .

HY-P0205A

Saralasin acetate hydrate [Sar1,Ala8] Angiotensin II acetate hydrate	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-W001158

N,N-Dimethylglycine hydrochloride 1 Publications Verification Dimethylglycine hydrochloride; DMG hydrochloride; N-Methylsarcosine hydrochloride	Endogenous Metabolite iGluR Amino Acid Derivatives	Neurological Disease Metabolic Disease
N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .

HY-P0205

Saralasin [Sar1,Ala8] Angiotensin II	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) is an octapeptide analog of angiotensin II. Saralasin is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P2625S

GLP-2(3-33) (Leu-13C6,15N)	Isotope-Labeled Compounds	Metabolic Disease
GLP-2(3-33) (Leu- ¹³C₆, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(3-33) (HY-P2625). GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM).

HY-P0205B

Saralasin TFA [Sar1,Ala8] Angiotensin II TFA	Angiotensin Receptor	Cardiovascular Disease Inflammation/Immunology
Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension .

HY-P2625S1

GLP-2(3-33) (Leu-13C6,15N) TFA	Isotope-Labeled Compounds GCGR	Metabolic Disease
GLP-2(3-33) (Leu- ¹³C₆, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(3-33) (HY-P2625). GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM).

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Cancer
MSG606 TFA is a potent human MC1 receptor antagonist (IC₅₀=17 nM). MSG606 TFA also partial agonist at human MC3 and MC5 receptors (EC₅₀ values are 59 and 1300 nM, respectively). MSG606 TFA exhibits binding affinity for A375 melanoma cells in vitro. MSG606 TFA reverses the induced hyperalgesia in female mice, with no effect in male mice.

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-P2055

A-57696	Peptides	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-P1793A

α-Casein (90-95) TFA	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) TFA is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) TFA inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) TFA inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) TFA activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) TFA can be used in the study of the mechanisms of allergic diseases and prostate cancer .

HY-P1793

α-Casein (90-95)	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) can be used in the study of the mechanisms of allergic diseases and prostate cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99794

Osocimab BAY 1213790	Factor Xa	Cardiovascular Disease
Osocimab (BAY 1213790), an anti-FXIa antibody (K_i=2.4 nM; EC₅₀=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .

HY-P99321

Teneliximab BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody	TNF Receptor	Inflammation/Immunology Cancer
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	Alkaloids Structural Classification Classification of Application Fields Leguminosae Source classification Pyridine Alkaloids Metabolic Disease Plants Thermopsis lanceolala R.Br. Disease Research Fields	nAChR
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-N11464

Kuwanon O	Structural Classification Flavonoids Flavones Source classification Crassulaceae Crassula hemisphaerica Thunb. Plants	Others
Kuwanon O is a flavonoid derivative with a fused dihydrochalcone partial moiety, that can be isolated from the root bark of Morus lhou (set.) Koidz .

HY-N8505

Lobelanine 8,10-Diphenyllobelidione	Alkaloids Piperidine Alkaloids Classification of Application Fields Source classification Other Diseases Campanulaceae Plants Disease Research Fields Lobelia chinensis Lour.	Others
Lobelanine (8,10-Diphenyllobelidione) is a chemical precursor for the biosynthesis of Lobeline. Lobeline is a partial nicotinic agonist and is used as a smoking cessation agent .

HY-N2364

Arecoline 2 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Areca catechu L. Source classification Metabolic Disease Plants Infection Alkaloids Piperidine Alkaloids Palmae Inflammation/Immunology Disease Research Fields	mAChR nAChR
Arecoline, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline also can induce oxidative stress .

HY-N15087

Lunatoic acid A	Structural Classification Natural Products Microorganisms Source classification	Bacterial
Lunatoic acid A has anti-mould (partial) and bacterial (individual) effects .

HY-N15088

Lunatoic acid B	Structural Classification Natural Products Microorganisms Source classification	Bacterial
Lunatoic acid B has anti-mould (partial) and bacterial (individual) effects .

HY-117526

(-)-Mesembrine	Alkaloids Source classification Aizoaceae Mesembryanthemum tortuosum Plants Indole Alkaloids	Endogenous Metabolite
(-)-Mesembrine, a psychoactive alkaloid, is a partial racemate in S. strictum and S. tortuosum in smaller amounts .

HY-N0175R

Cytisinicline (Standard)	Alkaloids Structural Classification Leguminosae Source classification Pyridine Alkaloids Plants Thermopsis lanceolala R.Br.	nAChR
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-N15180

Corynantheidine (-)-Corynantheidine	Structural Classification Alkaloids Source classification Rubiaceae Mitragyna speciosa Korth. Plants Indole Alkaloids	Opioid Receptor
Corynantheidine ((-)-Corynantheidine) is a mu-opioid receptor (MOR) partial agonist that shows MOR-dependent analgesic effects in mice .

HY-B0489A

Arecoline hydrochloride	Structural Classification Neurological Disease Classification of Application Fields Areca catechu L. Source classification Metabolic Disease Plants Infection Alkaloids Other Alkaloids Palmae Inflammation/Immunology Disease Research Fields	mAChR nAChR
Arecoline hydrochloride, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline hydrochloride exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline hydrochloride also can induce oxidative stress .

HY-N7687

Caulophyllogenin	Triterpenes Classification of Application Fields Leguminosae Terpenoids Source classification Acacia catechu (Linn. f.) Willd. Plants Disease Research Fields Inflammation/Immunology	PPAR
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-B0030

D-Cycloserine 4 Publications Verification	Structural Classification Microorganisms Antibiotics Resistance Selection Source classification Antibacterial Disease Research Other Antibiotics	iGluR Bacterial Antibiotic
D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research .

HY-B0489

Arecoline hydrobromide 2 Publications Verification methyl 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxylate hydrobromide	Structural Classification Neurological Disease Classification of Application Fields Areca catechu L. Source classification Metabolic Disease Plants Infection Alkaloids Other Alkaloids Palmae Inflammation/Immunology Disease Research Fields	mAChR nAChR
Arecoline hydrobromide, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline hydrobromide exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline hydrobromide also can induce oxidative stress .

HY-107803

Geranium oil	Structural Classification Natural Products Source classification Plants Geraniaceae	Estrogen Receptor/ERR
Geranium oil serves as a partial agonist for estrogen receptor (ER), enhancing both the cytotoxicity induced by Tamoxifen (TMX) (HY-13757A) in GT1-7 cells and the adverse effects of TMX on the central nervous system. Geranium oil can be utilized in the research of neurological disorders such as dementia .

HY-B0030R

D-Cycloserine (Standard)	Infection Structural Classification Microorganisms Neurological Disease Classification of Application Fields Antibiotics Source classification Endogenous metabolite Disease Research Fields Beta-lactam Antibiotics	iGluR Bacterial Antibiotic
D-Cycloserine (Standard) is the analytical standard of D-Cycloserine. This product is intended for research and analytical applications. D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research .

HY-N6869

Dehydroabietic acid	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-B0489R

Arecoline (hydrobromide) (Standard)	Alkaloids Structural Classification Areca catechu L. Other Alkaloids Source classification Palmae Plants	mAChR nAChR
Arecoline (hydrobromide) (Standard) is the analytical standard of Arecoline (hydrobromide). This product is intended for research and analytical applications. Arecoline hydrobromide, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline hydrobromide exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline hydrobromide also can induce oxidative stress .

HY-Y0511

N,N-Dimethylglycine 1 Publications Verification Dimethylglycine; DMG; N-Methylsarcosine	Structural Classification Microorganisms Other disease Classification of Application Fields Source classification Disease markers Other Diseases Amino acids Endogenous metabolite Disease Research Fields	Endogenous Metabolite iGluR Amino Acid Derivatives
N,N-Dimethylglycine (Dimethylglycine), a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine has antidepressant-like and surfactant effects .

HY-N1951

Miltirone 1 Publications Verification Rosmariquinone	Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Source classification Diterpenoids Plants	GABA Receptor Apoptosis Carboxylesterase (CES) SARS-CoV
Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC₅₀ of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; K_i = 0.04 μM) and SARS-CoV main protease (Mpro) .

HY-W002112

(±)-Nornicotine Nornicotine	Structural Classification Alkaloids Pyrrole Alkaloids Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Source classification Diterpenoids Plants	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N13944

Argyrin F	Structural Classification Natural Products Microorganisms Source classification	Apoptosis
Argyrin F a cyclic peptide with antitumoral activities. Argyrin F inhibits cell proliferation, migration, invasion and colony formation by partial induction of apoptosis and epithelial-mesenchymal transition (EMT). Argyrin F stabilizes p27 ^kip, up-regulated p21 ^waf1/cip1 and depletes COX2. Argyrin F can be used for the study of pancreatic ductal adenocarcinoma (PDAC) .

HY-N15177

Δ9-THCB Δ9-Tetrahydrocannabutol	Structural Classification Monophenols Cannabis sativa L Source classification Phenols Plants Moraceae	Cannabinoid Receptor
Δ9-THCB (Δ9-Tetrahydrocannabutol) has a high affinity for human CB1 and CB2 receptors with the K_i values of 15 nM and 51 nM, respectively. Δ9-THCB (Δ9-Tetrahydrocannabutol) has analgesic and anti-inflammatory activities and plays partial agonistic effects on CB1 receptor in mice .

HY-N2025

Oroxin A	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Metabolic Disease Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Disease Research Fields	PPAR Glycosidase
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-B0229

Zolmitriptan BW-311C90; 311C90	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Indole Alkaloids	5-HT Receptor Endogenous Metabolite
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

HY-Y0511R

N,N-Dimethylglycine (Standard) Dimethylglycine (Standard); DMG (Standard); N-Methylsarcosine (Standard)	Structural Classification Microorganisms Other disease Source classification Disease markers Amino acids Endogenous metabolite	Endogenous Metabolite iGluR Amino Acid Derivatives
N,N-Dimethylglycine (Dimethylglycine) (Standard) is the analytical standard of N,N-Dimethylglycine (HY-Y0511). This product is intended for research and analytical applications. N,N-Dimethylglycine (Dimethylglycine), a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine has antidepressant-like and surfactant effects.

HY-N2025R

Oroxin A (Standard)	Structural Classification Flavonoids Flavones Source classification Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz	PPAR Glycosidase
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-N0049

Nuciferine 5 Publications Verification	Structural Classification Alkaloids Aporphine Alkaloids other families Source classification Plants Isoquinoline Alkaloids	Parasite 5-HT Receptor Dopamine Receptor
Nuciferine is an antagonist at 5-HT_2A (IC₅₀=478 nM), 5-HT_2C (IC₅₀=131 nM), and 5-HT_2B (IC₅₀=1 μM), an inverse agonist at 5-HT₇ (IC₅₀=150 nM), a partial agonist at D₂ (EC₅₀=64 nM), D₅ (EC₅₀=2.6 μM) and 5-HT₆ (EC₅₀=700 nM), an agonist at 5-HT_1A (EC₅₀=3.2 μM) and D₄ (EC₅₀=2 μM) receptor.

HY-N0049R

Nuciferine (Standard)	Structural Classification Alkaloids other families Source classification Plants	Reference Standards 5-HT Receptor Dopamine Receptor
Nuciferine (Standard) is the analytical standard of Nuciferine. This product is intended for research and analytical applications. Nuciferine is an antagonist at 5-HT_2A (IC₅₀=478 nM), 5-HT_2C (IC₅₀=131 nM), and 5-HT_2B (IC₅₀=1 μM), an inverse agonist at 5-HT₇ (IC₅₀=150 nM), a partial agonist at D₂ (EC₅₀=64 nM), D₅ (EC₅₀=2.6 μM) and 5-HT₆ (EC₅₀=700 nM), an agonist at 5-HT_1A (EC₅₀=3.2 μM) and D₄ (EC₅₀=2 μM) receptor.

Cat. No.	Product Name	Chemical Structure

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-14546S

Aripiprazole-d8
Aripiprazole-d₈ is the deuterium labeled Aripiprazole, which is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

HY-14261S

Vilazodone-d8
Vilazodone-d₈ is the a deuterium labeled vilazodone, which is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist.

HY-126057S

(R)-Praziquantel-d11
(R)-Praziquantel-d₁₁ is the deuterium labeled (R)-Praziquantel. (R)-Praziquantel, the active enantiomer of Praziquantel, is a partial agonist of the human 5-HT2B receptor. (R)-Praziquantel acts as an antischistosomal eutomer .

HY-14546S1

Aripiprazole (1,1,2,2,3,3,4,4-d8) 5+ Cited Publications
Aripiprazole (1,1,2,2,3,3,4,4-d₈) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a K_i of 4.2 nM .

HY-15831

L-838417-d9
L-838417-d₉ is the deuterium labeled L-838417. L-838417 is a subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes .

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-Y1176S

Isonipecotic acid-d9
Isonipecotic acid-d₉ is the deuterium labeled Isonipecotic acid . Isonipecotic acid is a GABAA receptor partial agonist .

HY-114703S1

Eslicarbazepine-d4
Eslicarbazepine-d₄ (BIA 2-194-d₄) is deuterium labeled Eslicarbazepine. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.

HY-10019S2

Varenicline-13C15N

Varenicline- ¹³C ¹⁵N (CP 526555- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Varenicline. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10020S

Varenicline-15N3 hydrochloride

Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the ¹⁵N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-14153AS

Tegaserod-13C,d3 maleate
Tegaserod- ¹³C,d₃ (maleate) is the ¹³C- and deuterium labeled Tegaserod (maleate). Tegaserod maleate is a selective 5-HT4 receptor partial agonist and a 5-HT2B receptor antagonist. Tegaserod maleate exhibits a promotile effect throughout the gastrointestinal (GI) tract .

HY-P2625S

GLP-2(3-33) (Leu-13C6,15N)
GLP-2(3-33) (Leu- ¹³C₆, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(3-33) (HY-P2625). GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM).

HY-B0032AS

Lurasidone-d8
Lurasidone-d₈ is deuterium labeled Lurasidone. Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.

HY-17401S

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .

HY-W654010

Lurasidone-d8-1 hydrochloride
Lurasidone-d₈-1 (hydrochloride) is deuterium labeled Lurasidone (Hydrochloride). Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is an antagonist of both dopamine D₂ and 5-HT₇ with IC₅₀s of 1.68 and 0.495 nM, respectively. Lurasidone (Hydrochloride) (SM-13496 (Hydrochloride)) is also a partial agonist of 5-HT_1A receptor with an IC₅₀ of 6.75 nM .

HY-14262S1

Vilazodone-d8 hydrochloride
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active serotonin reuptake inhibitor (SSRI) and partial 5-HT₁A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

HY-14558S

Tandospirone-d8
Tandospirone-d₈ (SM-3997-d₈) is deuterium labeled Tandospirone. Tandospirone (SM-3997) is a potent and selective 5-HT_1A receptor partial agonist, with a K_i of 27 nM. Tandospirone has anxiolytic and antidepressant activities. Tandospirone can be used for the research of the central nervous system disorders and the underlying mechanisms .

HY-P2625S1

GLP-2(3-33) (Leu-13C6,15N) TFA
GLP-2(3-33) (Leu- ¹³C₆, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(3-33) (HY-P2625). GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM).

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC₅₀ values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.

HY-12752BS

Alimemazine-d6 hydrochloride

Alimemazine-d6 hydrochloride (Trimeprazine-d6 hydrochloride) is the deuterium labeled Alimemazine (HY-12752). Alimemazine is a phenothiazine derivative that is generally used as an antipruritic agent and also a hemagglutinin (HA)-receptor antagonist.Alimemazine (Trimeprazine) is also acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs. Alimemazine displays antiserotonin, antispasmodic, and antiemetic properties .

HY-G0021S

N-Desmethylclozapine-d8

N-Desmethylclozapine-d₈ is the deuterium labeled N-Desmethylclozapine. N-Desmethylclozapine is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine is a potent, allosteric and partial M1 receptors agonist (EC₅₀=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine is also a δ-opioid agonist .

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment .

HY-123689S

Samidorphan-d4

Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .

HY-G0021S1

N-Desmethylclozapine-d8 hydrochloride

N-Desmethylclozapine-d₈ (hydrochloride) is the deuterium labeled N-Desmethylclozapine hydrochloride. N-Desmethylclozapine hydrochloride is a major active metabolite of the atypical antipsychotic agent Clozapine. N-Desmethylclozapine hydrochloride is a potent, allosteric and partial M1 receptors agonist (EC₅₀=115 nM) and is able to potentiate hippocampal N-methyl-d-aspartate (NMDA) receptor currents through M1 receptor activation. N-Desmethylclozapine hydrochloride is also a δ-opioid agonist .

HY-123689S1

Samidorphan-d5

Samidorphan-d5 (ALKS-33-d5) is is a deuterated compound of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ-opioid, κ-opioid, and δ-opioid receptors. Samidorphan is a μ-opioid receptor antagonist and a partial agonist at k-opioid and δ-opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo .

HY-173251S

ENX-101
ENX-101 is an orally active (GABA_A) receptor partial positive allosteric modulator (PAM). ENX-101 is selective to α2β2γ2L (EC₅₀ = 0.76 nM), α2β3γ2L (EC₅₀ = 0.61 nM), α3 (EC₅₀ = 1.97 nM), α5 (EC₅₀ = 0.85 nM) subunits of GABA receptor. ENX-101 possesses antiseizure activity in several animal models .

HY-15394S1

(Rac)-Rotigotine-d3 hydrochloride

(Rac)-Rotigotine-d₃ hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-15414S

Vortioxetine-d8
Vortioxetine-d₈ (Lu AA 21004-d₈) is a deuterated version of Vortioxetine. Vortioxetine (Lu AA 21004) is an antagonist of 5-HT_3A and 5-HT₇ receptors (K_i: 3.7 nM, 19 nM) and an inhibitor of 5-hydroxytryptamine transporter (SERT) (K_i: 1.6 nM), as well as a 5-HT_1A agonist and a partial 5-HT_1B agonist (K_i: 15 nM, 33 nM) .

HY-133152S

Brexpiprazole S-oxide-d8

Brexpiprazole S-oxide-d₈ is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM .

HY-W001158S1

N,N-Dimethylglycine-d3 hydrochloride

N,N-Dimethylglycine-d₃ (Dimethylglycine-d₃) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .

HY-15414S2

Vortioxetine-d4
Vortioxetine-d₄ (Lu AA 21004-d₄) is the deuterium labeled Vortioxetine (HY-15414). Vortioxetine is an antagonist of 5-HT3A and 5-HT7 receptors (K_i: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (K_i: 1.6 nM), as well as a 5-HT1A agonist and a partial agonist of 5-HT1B (K_i: 15 nM, 33 nM) .

HY-17637S2

Lumateperone-d4

Lumateperone-d₄ (ITI-007-d₄) is deuterium labeled Lumateperone. Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used for the study of schizophrenia and bipolar depression .

HY-15394S

(Rac)-Rotigotine-d7 hydrochloride

(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-W002112S1

(±)-Nornicotine-d7

(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-15414AS

Vortioxetine-d8 hydrobromide
Vortioxetine-d₈ (Lu AA 21004-d₈) hydrobromide is the deuterated form of Vortioxetine. Vortioxetine (Lu AA 21004) is an antagonist of 5-HT_3A and 5-HT₇ receptors (K_i: 3.7 nM, 19 nM) and an inhibitor of 5-hydroxytryptamine transporter (SERT) (K_i: 1.6 nM), as well as a *5-HT_1A agonist and a partial* 5-HT_1B agonist (K_i: 15 nM, 33 nM) .**

HY-W002112S

(±)-Nornicotine-d4

(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-15414S3

Vortioxetine-d3
Vortioxetine-d₃ (Lu AA 21004-d₃) is a deuterium labeled Vortioxetine (HY-15414). Vortioxetine (Lu AA 21004) is an antagonist of 5-HT_3A and 5-HT₇ receptors (K_i: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (K_i: 1.6 nM), as well as a 5-HT_1A agonist and a partial agonist of 5-HT_1B (K_i: 15 nM, 33 nM) .

HY-19733S

Lumateperone-13C,d3 tosylate

Lumateperone- ¹³C,d₃ (ITI-007- ¹³C,d₃) tosylate is ¹³C and deuterium labeled Lumateperone (tosylate). Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia .

HY-W001158S

N,N-Dimethylglycine-d6 hydrochloride

N,N-Dimethylglycine-d₆ (Dimethylglycine-d₆) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .

HY-15414S1

Vortioxetine-d6
Vortioxetine-d6 (Lu AA 21004-d6) is the deuterium labeled Vortioxetine (HY-B1490A). Vortioxetine (Lu AA 21004) is an antagonist of 5-HT_3A and 5-HT₇ receptors (K_i: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (K_i: 1.6 nM), as well as a 5-HT_1A agonist and a partial agonist of 5-HT_1B (K_i: 15 nM, 33 nM) .

HY-B0072S

Tropisetron-d5

Tropisetron-d₅ (SDZ-ICS-930-d₅ (free base)) is deuterium labeled Tropisetron. Tropisetron (SDZ-ICS-930 free base) is an orally active anti-inflammatory and antiemetic agent. Tropisetron is 5-HT₃R antagonists with a K_i of 5.3 nM. Tropisetron is also a partial agonist of α7 nicotinic receptor (α7 nAChR) with an EC₅₀ of 1.3 μM. In addition, Tropisetron has antitumor and neuroprotective effects .

HY-B0229S

Zolmitriptan-d6
Zolmitriptan-d₆ is deuterium labeled Zolmitriptan. Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

HY-B0731AS

Perospirone-d8

Perospirone-d₈ (SM-9018-d₈ (free base)) is deuterium labeled Perospirone. Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT_2A receptor (K_i=0.6 nM) and dopamine D₂ receptor (K_i=1.4 nM), and also a partial agonist of 5-HT_1A receptor (K_i=2.9 nM). Perospirone is an atypical antipsychotic agent and has the potential for schizophrenic disease research .

HY-15780S

Brexpiprazole-d8

Brexpiprazole-d₈ (OPC-34712-d₈) is the deuterium labeled Brexpiprazole (HY-15780). Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D_2L receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) ^.

HY-15780S1

Brexpiprazole-d8-1

Brexpiprazole-d₈-1 (OPC-34712-d₈-1) is the deuterium labeled Brexpiprazole (HY-15780) . Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D_2L receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (K_i=0.17 nM) and α2C receptors (K_i=0.59 nM) .

Cat. No.	Product Name		Classification

HY-103476

Ro15-4513		Azide
Ro15-4513, imidazobenzodiazepinone derivative, is a partial inverse agonist of benzodiazepine receptor (BZR) . Ro15-4513 is a potent ethanol antagonist . Ro15-4513 has anti-anxiety effect . Ro15-4513 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-128855

Talsaclidine		Alkynes
Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes . Talsaclidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-108039

Bezisterim HE 3286; NE-3107		Alkynes
Bezisterim (HE 3286; NE-3107) is a synthetic derivative of a natural anti-inflammatory steroid, β-AET. Bezisterim is an orally active partial NF-κB inhibitor. HE3286 reduces proinflammatory signals, including IL-6 and matrix metallopeptidase 3. Bezisterim freely penetrates the blood brain barrier in mice. Bezisterim can be used for the research of the ulcerative colitis, arthritis, experimental autoimmune encephalomyelitis . Bezisterim is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-173115

15-LOX-IN-2		Alkynes
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .

Cat. No.	Product Name		Classification